What question did this study set out to answer?

To quantify the deposition of cutaneous phosphorylated alpha-synuclein in patients with mild cognitive impairment related to Alzheimer's disease and dementia with Lewy bodies.

June 13, 2026

The Syn-D Study: Detection of Longitudinal Changes in Cutaneous Phosphorylated Alpha-Synuclein in Mild Cognitive Impairment (S42.010)

Puntos clave

To quantify the deposition of cutaneous phosphorylated alpha-synuclein in patients with mild cognitive impairment related to Alzheimer's disease and dementia with Lewy bodies.
Investigation of phosphorylated alpha-synuclein in skin samples from participants with mild cognitive impairment.
Comparison of results between patients diagnosed with Alzheimer's disease and those with dementia with Lewy bodies.
Identified significant levels of phosphorylated alpha-synuclein in patients with mild cognitive impairment.
Demonstrated a correlation between the cutaneous deposition and clinical markers of Alzheimer's and Lewy body dementia.

Resumen

To quantify cutaneous phosphorylated alpha-synuclein (P-SYN) deposition in patients with mild cognitive impairment (MCI) due to suspected Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB).

Me gusta

Guardar